BETHESDA 2014: WHY?
The past decade has witnessed several changes in the realm of cervical cancer screening, prevention, and management. These include the increased use of liquid-based preparations; the addition of cotesting (Pap and hrHPV testing) and, more recently, primary hrHPV testing as additional screening options; further insights into HPV biology; changes in histopathology terminology; approval and implementation of prophylactic HPV vaccines; and updated guidelines for cervical cancer screening and clinical management.
Ler o artigo completo aqui.
Article first published online: 1 MAY 2015
doi:10.1002/cncy.21521
Citation: [Nayar, R. and Wilbur, D. C. (2015), The Pap test and Bethesda 2014. Cancer Cytopathology, 123: 271–281. doi: 10.1002/cncy.21521]
Copyright: © 2015 S. Karger AG, Basel.
From: US National Library of Medicine <http://www.nlm.nih.gov/> – National Institutes of Health <http://www.nih.gov/>
Disclaimer: http://www.ncbi.nlm.nih.gov/ About/disclaimer.html
ola, eu estou estudando esse conteudo na disciplina de Citologia Clinica, achei interessante sua postagem.. sou do Brasil…. obg
Olá Zilmar,
Muito obrigado pelas palavras de incentivo. Desejo que tudo lhe corra bem.